Natixis Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Natixis Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,907	Closed	-$322K	–	1160
2019 Q4	$322K	Hold	1,907	–	–	﹤0.01%	1090
2019 Q3	$354K	Hold	1,907	–	–	﹤0.01%	1064
2019 Q2	$436K	Sell	1,907 -2,066	-52%	-$404K	﹤0.01%	1017
2019 Q1	$835K	Sell	3,973 -8	-0.2%	-$1.5K	0.01%	941
2018 Q4	$457K	Sell	3,981 -3,323	-45%	-$492K	﹤0.01%	1023
2018 Q3	$1.68M	Sell	7,304 -161	-2%	-$35.6K	0.01%	817
2018 Q2	$1.66M	Sell	7,465 -251	-3%	-$56.1K	0.02%	807
2018 Q1	$1.76M	Sell	7,716 -4,474	-37%	-$1.18M	0.02%	772
2017 Q4	$3.19M	Sell	12,190 -33	-0.3%	-$7.74K	0.03%	555
2017 Q3	$2.74M	Sell	12,223 -142	-1%	-$34.9K	0.03%	625
2017 Q2	$3.38M	Buy	+12,365	New	+$3.35M	0.04%	553

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Natixis Advisors's AXDX Position: Q1 2020 in Review

Natixis Advisors sold out of Accelerate Diagnostics (AXDX) in Q1 2020, closing a stake of 1,907 shares — an estimated $322K sold.

Natixis Advisors first reported a position in AXDX in Q2 2017 and held it in 11 quarters. The position peaked at $3.38M in Q2 2017. 110 funds tracked by Wall St. Rank hold AXDX as of Q1 2020.

Natixis Advisors reported no remaining Accelerate Diagnostics position as of Q1 2020 after selling out during the quarter.
Natixis Advisors sold 1,907 Accelerate Diagnostics shares in Q1 2020, an estimated $322K.
Natixis Advisors first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 11 quarters.
Natixis Advisors's Accelerate Diagnostics position peaked at $3.38M in Q2 2017.
110 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2020.

Based on Natixis Advisors's 13F filing for Q1 2020, filed 27 Apr 2020.